Skip to main content

Advertisement

SpringerLink
Log in

Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD)

  • ORIGINAL ARTICLE
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

The number of patients with chronic kidney disease (CKD) in Japan is currently rising. Therefore, measures to control the progression of CKD from a predialysis condition to endstage renal failure are urgently required. We are conducting a clinical trial to investigate the efficacy of an oral carbonaceous adsorbent (Kremezin) in patients at the predialysis stage of progressive chronic kidney disease (the Carbonaceous oral Adsorbent's effectiveness on Progression of chronic Kidney Disease [CAP-KD] trial).

Methods

A multidisciplinary treatment regimen, consisting of antihypertensive therapy (using an angiotensin-converting-enzyme inhibitor and/or an angiotensin II receptor blocker) and a low-protein diet is conventionally used to treat patients with kidney disease. To assess the efficacy of Kremezin in preventing the progression of CKD, we compare two groups of patients, receiving either conventional treatment alone or such treatment paired with Kremezin. The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel-group comparison clinical trial and will be conducted as a researcher-directed study. The primary endpoint of this study is the time to the first event of a composite endpoint, comprising the following: (1) a doubling of serum creatinine (sCr); (2) an increase in sCr level to 6.0 mg/dl or more; (3) endstage renal disease (defined as that requiring dialysis or renal transplantation); and (4) death. Secondary endpoints are as follows: (1) variation in urinary protein; (2) changes in creatinine clearance rate; (3) changes in health-related quality of life; and (4) adverse events. The total number of patients (putative) in this trial will be 450, with 225 patients in each group. Enrollment will take place over 2 years, with a 1-year follow-up period.

Results

As this is an ongoing trial, results are not yet available.

Conclusions

We believe that the CAP-KD trial is a well-designed study that will provide internationally relevant evidence concerning the outcomes of treatment in Japanese patients with CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. InstitutionalAuthorNameJapanese Society for Dialysis Therapy Statistics Investigation Committee (2004) ArticleTitleAn overview of regular dialysis treatment in Japan (as of 31 Dec 2001) Ther Apher Dial 8 1–32

    Google Scholar 

  2. S Klahr AS Levey GJ Beck AW Caggiula L Hunsicker JW Kusek et al. (1994) ArticleTitleThe effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease: Modification of Diet in Renal Disease Study Group N Engl J Med 330 877–84 Occurrence Handle10.1056/NEJM199403313301301 Occurrence Handle8114857

    Article  PubMed  Google Scholar 

  3. InstitutionalAuthorNameModification of Diet in Renal Disease Study Group (1996) ArticleTitleEffect of dietary protein restriction on the progression of moderate renal disease in the Modification of Diet in Renal Disease Study J Am Soc Nephrol 7 2616–26

    Google Scholar 

  4. InstitutionalAuthorNameHeart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) ArticleTitleEffects of ramipril on cardiovascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 253–9

    Google Scholar 

  5. M Ravid H Savin I Jutrin T Bental B Katz M Lishner et al. (1993) ArticleTitleLong-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 577–81 Occurrence Handle8452322

    PubMed  Google Scholar 

  6. G Maschio D Alberti G Janin F Locatelli JF Mann M Motolese et al. (1996) ArticleTitleEffect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Research Group N Engl J Med 334 939–45 Occurrence Handle10.1056/NEJM199604113341502 Occurrence Handle8596594

    Article  PubMed  Google Scholar 

  7. InstitutionalAuthorNameThe GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nephrologia) (1997) ArticleTitleRandomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy Lancet 349 1857–63

    Google Scholar 

  8. BM Brenner ME Cooper D de Zeeuw WF Keane WE Mitch HH Parving InstitutionalAuthorNamefor the RENAAL Study Investigators et al. (2001) ArticleTitleEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861–9 Occurrence Handle11565518

    PubMed  Google Scholar 

  9. EJ Lewis LG Hunsicker WR Clarke T Berl MA Pohl JB Lewis InstitutionalAuthorNamefor the Collaborative Study Group et al. (2001) ArticleTitleRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes N Engl J Med 345 851–60 Occurrence Handle10.1056/NEJMoa011303 Occurrence Handle11565517

    Article  PubMed  Google Scholar 

  10. HH Parving H Lehnert J Brochner-Mortensen R Gomis S Andersen P Arner InstitutionalAuthorNamefor the Irbesartan in Patients with Type-2 Diabetes and Microalbuminuria Study Group (2001) ArticleTitleThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870–8 Occurrence Handle10.1056/NEJMoa011489 Occurrence Handle11565519

    Article  PubMed  Google Scholar 

  11. N Nakao A Yoshimura H Morita M Takada T Kayano T Ideura (2003) ArticleTitleCombination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme-inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial Lancet 361 117–24 Occurrence Handle10.1016/S0140-6736(03)12229-5 Occurrence Handle12531578

    Article  PubMed  Google Scholar 

  12. T Akizawa K Koide S Koshikawa (1998) ArticleTitleEffects of Kremezin on patients with chronic renal failure: results of a nationwide clinical study Kidney and Dialysis 45 373–88

    Google Scholar 

  13. S Koshikawa et al. (1987) ArticleTitleThe effect of AST-120 on the course of chronic renal insufficiency Kidney and Dialysis 22 373–81

    Google Scholar 

  14. K Koide S Koshikawa K Yamane S Hidaka H Sekino M Saito et al. (1987) ArticleTitleClinical evaluation of AST-120 on suppression of progression of chronic renal failure: multi-center, double-blind study in comparison with placebo Clinical Evaluation 15 527–64

    Google Scholar 

  15. SJ Pocock R Simon (1975) ArticleTitleSequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 1 103–1

    Google Scholar 

  16. M Horio Y Orita S Manabe M Sakata M Fukunaga (1997) ArticleTitleFormula and nomogram for predicting creatinine clearance from serum creatinine concentration Clin Exp Nephrol 1 110–4

    Google Scholar 

  17. J Ware M Kosinski J Dewey (2000) How to score version 2 of SF-36R health survey QualityMetric Lincoln, RI

    Google Scholar 

  18. SD Mark JM Robins (1993) ArticleTitleA method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Controlled Clin Trials 14 79–97

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Health Care Research, Kyoto University Graduate School of Medicine, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan

    Satoshi Morita & Shunichi Fukuhara

  2. Center of Blood Purification Therapy, Wakayama Medical School, Wakayama, Japan

    Tadao Akizawa

  3. Department of Internal Medicine, Jichi Medical School and Sashima Red Cross Hospital, Tochigi, Japan

    Yasushi Asano

  4. The Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan

    Kiyoshi Kurokawa

Authors
  1. Satoshi Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shunichi Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tadao Akizawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasushi Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kiyoshi Kurokawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Satoshi Morita.

About this article

Cite this article

Morita, S., Fukuhara, S., Akizawa, T. et al. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol 9, 219–227 (2005). https://doi.org/10.1007/s10157-005-0358-7

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-005-0358-7

Key words

Search

Navigation